黄葵胶囊联合ACEI/ARB治疗糖尿病肾病的系统评价与Meta分析
该系统评价纳入32项RCT共2881例糖尿病肾病患者,评估黄葵胶囊联合RASI的疗效与安全性。结果显示联合治疗在降低24h-UTP、UAER、UACR、Scr和BUN方面优于单用RASI,且未增加不良反应,但异质性显著,结论需谨慎解读。
要点
- 黄葵胶囊联合RASI可显著降低DKD患者蛋白尿及肾功能指标。
- 联合治疗未增加额外不良反应,安全性尚可。
- 亚组提示联合ARB降UAER似优于ACEI,高蛋白尿或高Scr者获益更明显。
核心结论
- 与单用RASI相比,黄葵胶囊联合RASI可能是治疗DKD的更优策略。
- 因异质性显著,结果需谨慎解读,尚需更多高质量RCT验证。
研究设计与样本
- 系统评价与Meta分析,检索Pubmed、Cochrane Library、Embase、CNKI、SinoMed、WF、VIP等中英文数据库。
- 纳入32项RCT,共2881例DKD患者,治疗组1442例,对照组1439例。
- 采用Cochrane偏倚风险评估工具评价质量,RevMan 5.4软件进行Meta分析。
主要发现
- 联合治疗降低24h-UTP:MD=-442.05,95%CI(-609.72,-274.38),p<0.00001。
- 联合治疗降低UAER:MD=-30.53,95%CI(-39.10,-21.96),p<0.00001。
- 联合治疗降低UACR:MD=-157.93,95%CI(-288.60,-27.25),p<0.00001。
- 联合治疗降低Scr:MD=-6.80,95%CI(-9.85,-3.74),p<0.0001。
- 联合治疗降低BUN:MD=-0.59,95%CI(-1.07,-0.12),p=0.01。
关键数值与推荐
- 亚组分析提示黄葵胶囊联合ARB降UAER似优于联合ACEI。
- 24h-UTP>2 g或Scr>110-133 μmol/L及>133 μmol/L的DKD患者加用黄葵胶囊降Scr可能更显著。
临床怎么用
- 对DKD患者可考虑在RASI基础上联用黄葵胶囊以降低蛋白尿和改善肾功能指标。
- 联合治疗未增加不良反应,但仍需监测安全性。
- 因异质性大,应用时应结合患者分期及蛋白尿水平个体化决策。
局限性
- 纳入研究异质性显著,影响结果可靠性。
- 缺乏多中心、大样本、不同DKD分期及长期随访的高质量RCT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Diabetic kidney disease (DKD) is one of the most serious microvascular complications of diabetes, with the incidence rate increasing yearly, which is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease. Abelmoschus Manihot capsule, as a proprietary Chinese patent medicine, is widely used for treating CKD in China. Currently, the combination of Abelmoschus Manihot (AM) capsule and renin-angiotensin-aldosterone system inhibitor (RASI) has gained popularity as a treatment option for DKD, with more and more randomized control trials (RCTs) in progress. However, the high-quality clinical evidence supporting its application in DKD is still insufficient. Aim of the study: To comprehensively and systematically evaluate the efficacy and safety of AM capsule combined with RASI in the treatment of DKD. Materials and methods: English and Chinese databases such as Pubmed, Cochrane Library, Embase, CNKI, SinoMed, WF, and VIP were searched to collect the RCTs of AM capsule in treatment of DKD. Then Two investigators independently reviewed and extracted data from the RCTs which met the inclusion criteria. The quality of the data was assessed using the Cochrane risk of bias assessment tool, and meta-analysis was performed using RevMan 5.4 software. Results: 32 RCTs with a total of 2,881 DKD patients (1,442 in the treatment group and 1,439 in the control group) were included. The study results showed that AM capsule combined with RASI could be more effective in decreasing 24h-UTP [MD = -442.05, 95% CI (-609.72, -274.38), p < 0.00001], UAER [MD = -30.53, 95% CI (-39.10, -21.96), p < 0.00001], UACR [MD = -157.93, 95% CI (-288.60, -27.25), p < 0.00001], Scr [MD = -6.80, 95% CI (-9.85, -3.74), p < 0.0001], and BUN [MD = -0.59, 95% CI (-1.07, -0.12), p = 0.01], compared to using RASI alone. According to the subgroup analyses, the combination of AM and ARB seems to be more effective in reducing UAER than the combination of ACEI, and the addition of AM may achieve a more significant clinical effect on decreasing Scr for DKD patients with 24h-UTP>2 g or Scr>110-133 μmol/L and >133 μmol/L. Furthermore, no additional adverse reactions were observed in the combination group [OR = 1.06; 95%CI: (0.66, 1.69), p = 0.82]. Conclusion: Combining AM with RASI may be a superior strategy for DKD treatment compared to RASI monotherapy. However, due to significant heterogeneity, the results should be interpreted with great caution, and more high-quality RCTs with multi-centers, different stages of DKD, large sample sizes, and long follow-up periods are still needed to improve the evidence quality of AM for DKD in the future. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/#recordDetails; Identifier CRD42022351422.
引用
- Tan Y, Zhang Z, Zhou P, et al. Efficacy and safety of Abelmoschus manihot capsule combined with ACEI/ARB on diabetic kidney disease: a systematic review and meta analysis. Front Pharmacol. 2024. PMID: 38249351. doi:10.3389/fphar.2023.1288159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。